An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

This open-label, Phase IIa study (n=12) evaluates the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 (5-MeO-DMT) combined with relapse prevention psychological support for patients with Alcohol Use Disorder (AUD).

Conducted by Beckley Psytech Ltd, the trial aims to explore the potential effects of BPL-003 on alcohol use and related symptoms. Approximately 12 eligible participants will receive a single intranasal dose of BPL-003, with 12 weeks of follow-up assessments. Psychological support will be provided before, during, and after dosing.

The study started on May 30, 2023, and was estimated to be completed by October 2023.

Topic Alcohol Use Disorder Addiction
Compound 5-MeO-DMT
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.